Study Condition(s): Adult Type 2 Diabetes

An Administration Method Study of Human Regular U-500 Insulin (LY041001) in Participants with Type 2 Diabetes Mellitus (VIVID)

Study Alias: IBHD

Study Identifier(s): Tool Tip Icon {{ defaultRegistry.registryAnchorText }} NCT02561078 {{ currentLocaleObject.registryAnchorText }}

Completed Completed

Study Purpose

The main purpose of this study is to evaluate the safety and efficacy of Human Regular U-500 Insulin Administered by Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Injections in Subjects With Type 2 Diabetes Mellitus

Completed Study

The results of this study are not yet available.

Who Participated? Tool Tip Icon

Here you can find out a bit more about the requirements for volunteers who took part in this study

Gender

Male Female

Age

18 years
85 years

Time Commitment

Your participation could last up to 26 weeks and include 10 visits to the study center
  • Participant must be diagnosed with type 2 diabetes mellitus (T2DM)

  • Participant must not be diagnosed with type 1 diabetes mellitus (T1DM) or other types of diabetes apart from T2DM

  • Participant must have been on the same insulin for >3 months and have a current Total Daily Dose of insulin >200 units but < 600 units

  • Participant must not have a history of more than 1 episode of severe hypoglycemia requiring the assistance of another person, resulting in coma, seizures or disorientation within the 6 months prior to study entry

  • Participant must not have chronic kidney disease Stage 4 and higher, or history of renal transplantation

  • Participant must not have had a blood transfusion or severe blood loss within 3 months prior to screening or have known hemoglobinopathy, hemolytic anemia, or sickle cell anemia

  • Participant must not have used any weight loss drugs in the 3 months prior to screening

  • Participant must not have a history of bariatric surgery including Roux-en-Y gastric bypass surgery, gastric banding, and/or gastric sleeve

  • Female participant must not be pregnant or breastfeeding, or intend to become pregnant during the course of the study

  • Male participant must agree to practice a medically acceptable birth control method

Where This Study Took Place Tool Tip Icon

57 locations participated
Invalid Postal Code.
Please re-enter postal code.

{{sites.getPageStartCount()}} - {{sites.getPageEndCount()}} of {{sites.totalCount}} Results

0 of {{sites.totalCount}} Results

Distance Location
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
,
Closest Location
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
,
Other Location(s)
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
,

To improve your experience on Lilly TrialGuide, please use the latest version of Chrome, Firefox, Safari, or Internet Explorer, with Java Script enabled.
This website is not optimized for your browser, as configured.